Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

STRIDE-1: A Randomized, Double-blind, Active-controlled Trial to Assess the Efficacy and Safety of AXS-05 Administered Orally to Subjects With Treatment Resistant Major Depressive Disorder

NCT02741791 is registered in ClinicalTrials.gov with Axsome Therapeutics, Inc. as lead sponsor.

NCT NCT02741791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02741791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
STRIDE-1: A Randomized, Double-blind, Active-controlled Trial to Assess the Efficacy and Safety of AXS-05 Administered Orally to Subjects With Treatment Resistant Major Depressive Disorder
Lead sponsor
Axsome Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2016
Completion date
March 20, 2020
Enrollment
312 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

treatment resistant major depressive disorder